Pain Control in Children and Adolescent After Thoracic Surgery: The Effect of Gabapentin
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03393702 |
Recruitment Status :
Completed
First Posted : January 8, 2018
Last Update Posted : September 8, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pain, Postoperative Surgery, Thoracic | Drug: Gabapentin Drug: Placebo | Phase 4 |
The subjects are randomized to the Gabapentin or Placebo group. All patients receive preoperative gabapentin (15 mg/kg, treatment) or placebo, respectively and after surgery either gabapentin (7,5 mg/kg, treatment) or placebo 2 times per day for 3 days, respectively.
Patients are subjected to the same anaesthesia protocol. Postoperative analgesia are achieved with either continuous ropivacaine 0.2%/fentanyl 5.0 μg/ml infusion through a thoracic epidural catheter (N=40; Gabapentin n=20, Placebo n=20), or intravenous infusion of morphine (N=40; Gabapentin n=20, Placebo n=20). All patients receive acetaminophen and non-steroidal anti-inflammatory drugs, and metamizol as a "rescue drug"
The intravenous infusion of morphine grup was expanded on the basis of the bioethics commission's decision KB-125/2019 (N=64; Gabapentin n=32, Placebo n=32).
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 104 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Efficacy of Gabapentin as Adjuvant for Postoperative Pain in Pediatric Thoracic Surgery - a Randomized Quadruple Blind Study |
Actual Study Start Date : | May 9, 2017 |
Actual Primary Completion Date : | December 30, 2019 |
Actual Study Completion Date : | December 3, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Gabapentin
|
Drug: Gabapentin
Other Name: Gabapentin TEVA, capsules |
Placebo Comparator: Placebo Control
|
Drug: Placebo
|
- Pain intensity scores at rest (FLACC for patients <7 y.o., NRS for patients >7 y.o.) [ Time Frame: postoperative day: 0-3 ]
- Pain intensity scores during deep breathing (FLACC for patients <7 y.o., NRS for patients >7 y.o.) [ Time Frame: postoperative day: 0-3 ]
- Pain intensity scores during coughing (FLACC for patients <7 y.o., NRS for patients >7 y.o.) [ Time Frame: postoperative day: 0-3 ]
- Total ropivacaine/fentanyl consumption. [ Time Frame: postoperative day: 0-3 ]
- Total morphine consumption. [ Time Frame: postoperative day: 0-3 ]
- Anxiety intensity scores. [ Time Frame: before surgery, postoperative day 3 ]Patients rate their anxiety using State-Trait Anxiety Inventory.
- Side Effect Occurrence [ Time Frame: first 3 days after surgery ]Incidence and severity of nausea, vomiting, pruritis, sedation, dizziness, urinary retention, complication in relation to administering of the drugs to epidural space.
- The number of doses of metamizol as a "rescue drug" [ Time Frame: postoperative day: 0-3 ]
- Patient satisfaction. [ Time Frame: first 3 days after surgery ]Responses can range from 0 (very dissatisfied) to 10 (very satisfied).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 5 Years to 18 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 5 - 18 years of age;
- surgery: lateral thoracotomy or Ravitch procedure;
- ASA 1-3;
- postoperative analgesia: thoracic epidural analgesia or intravenous infusion of morphine.
Exclusion Criteria:
- allergy or sensitivity to gabapentin;
- history of chronic pain or daily analgesic use;
- diagnosed with psychiatric disorders;
- treated oncologically;
- with impaired verbal communication;
- the lack of postoperative chest drainage.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03393702
Poland | |
Institute for Tuberculosis and Lung Diseases, Pediatric Division | |
Rabka-Zdrój, Małopolska, Poland, 34-700 |
Study Director: | Lucyna Tomaszek, PhD | National Institute for Tuberculosis and Lung Diseases, Poland |
Responsible Party: | Lucyna Tomaszek, PhD, RN, Head of Nursing, Specialist Nurse in Anesthesia and Intensive Care, National Institute for Tuberculosis and Lung Diseases, Poland |
ClinicalTrials.gov Identifier: | NCT03393702 |
Other Study ID Numbers: |
10.11 |
First Posted: | January 8, 2018 Key Record Dates |
Last Update Posted: | September 8, 2021 |
Last Verified: | August 2021 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Postoperative pain Anxiety Postoperative Complications Patient Satisfaction |
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Neurologic Manifestations Gabapentin Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
Anticonvulsants Anti-Anxiety Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Antimanic Agents |